REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Sponsor
Novo Nordisk A/S (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06065540
Collaborator
(none)
2,700
332
7
27.6
8.1
0.3
Study Details
Study Description
Brief Summary
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
2700 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Anticipated Study Start Date
:
Sep 27, 2023
Anticipated Primary Completion Date
:
Nov 26, 2025
Anticipated Study Completion Date
:
Jan 14, 2026
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CagriSema 2.4 mg/2.4 mg Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. |
Drug: Cagrilintide
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
|
| Experimental: CagriSema 1.0 mg/1.0 mg Participants will receive once-weekly s.c injections of 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks. |
Drug: Cagrilintide
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
|
| Active Comparator: Semaglutide 2.4 mg Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 68 weeks. |
Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
|
| Active Comparator: Semaglutide 1.0 mg Participants will receive once-weekly s.c injection of 1.0 mg semaglutide for 68 weeks. |
Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
|
| Active Comparator: Cagrilintide 2.4 mg Participants will receive once-weekly s.c injection of 2.4 mg cagrilintide for 68 weeks. |
Drug: Cagrilintide
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
|
| Placebo Comparator: Placebo 2.4 mg/2.4 mg Participants will receive once-weekly s.c injection of placebo matched to 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. |
Drug: Placebo cagrilintide
Participants will receive placebo matched to cagrilintide subcutaneously.
Drug: Placebo semaglutide
Participants will receive placebo matched to semaglutide subcutaneously.
|
| Placebo Comparator: Placebo 1.0 mg/1.0 mg Participants will receive once-weekly s.c injection of placebo matched to 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks. |
Drug: Placebo cagrilintide
Participants will receive placebo matched to cagrilintide subcutaneously.
Drug: Placebo semaglutide
Participants will receive placebo matched to semaglutide subcutaneously.
|
Outcome Measures
Primary Outcome Measures
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage.
Secondary Outcome Measures
- CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg: Change in HbA1c [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg: Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage.
- CagriSema 2.4 mg/2.4 mg versus semaglutide 1.0 mg: Change in HbA1c [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema 2.4 mg/2.4 mg versus semaglutide 1.0 mg: Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage.
- Cagrilintide 2.4 mg versus placebo: Change in HbA1c [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- Cagrilintide 2.4 mg versus placebo: Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of greater than or equal to (>=) 10 percent (%) weight reduction [From baseline (week 0) to end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of >= 15 % weight reduction [From baseline (week 0) to end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of >= 20 % weight reduction [From baseline (week 0) to end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 millimoles per litre (mmol/L) (70-140 milligrams per decilitre [mg/dL]) [From baseline (week -3) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Systolic Blood Pressure (SBP) [From baseline (week 0) to end of treatment (week 68)]
Measured in millimeters of mercury (mmHg).
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in triglycerides [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of triglycerides.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of non-HDL cholesterol.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) [From baseline (week -3) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP) [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of hsCRP.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Fasting Plasma Glucose (FPG) [From baseline (week 0) to end of treatment (week 68)]
Measured in mmol/L.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol]) [At end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol) [At end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL) [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL) [From baseline (week 0) to end of treatment (week 68)]
Measured in percentage-points.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Within-day glycaemic variability (% coefficient of variation [CV]) [At end of treatment (week 68)]
Measured in percentage.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Achievement of ≥ 5 % weight reduction [From baseline (week 0) to end of treatment (week 68)]
Measured as count of participants.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in waist circumference [From baseline (week 0) to end of treatment (week 68)]
Measured in centimetre.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Diastolic Blood Pressure (DBP) [From baseline (week 0) to end of treatment (week 68)]
Measured in mmHg.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in total cholesterol [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of total cholesterol.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in HDL cholesterol [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of HDL cholesterol.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in low-density lipoprotein (LDL) cholesterol [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of LDL cholesterol.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of VLDL.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in free fatty acids [From baseline (week 0) to end of treatment (week 68)]
Measured as ratio of free fatty acids.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Short Form (SF)-36v score- Physical component summary score [From baseline (week 0) to end of treatment (week 68)]
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in SF-36v2 score- Mental component summary score [From baseline (week 0) to end of treatment (week 68)]
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score [From baseline (week 0) to end of treatment (week 68)]
DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control.
- CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score [From baseline (week 0) to end of treatment (week 68)]
TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state.
- CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of treatment emergent adverse events (TEAEs) [From baseline (week 0) to end of study (week 75)]
Measured as count of events.
- CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter) [From baseline (week 0) to end of study (week 75)]
Measured as count of episodes.
- CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3) [From baseline (week 0) to end of study (week 75)]
Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Male or female.
-
Age 18 years or above at the time of signing the informed consent.
-
Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
-
Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
-
Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
-
Body Mass Index (BMI) greater than or equal to 25 kilogram per square metre ( kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
Exclusion Criteria:
-
Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m^2) as determined by central laboratory at screening.
-
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
-
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novo Nordisk Investigational Site | Birmingham | Alabama | United States | 35211 |
| 2 | Novo Nordisk Investigational Site | Birmingham | Alabama | United States | 35294 |
| 3 | Novo Nordisk Investigational Site | Pelham | Alabama | United States | 35124 |
| 4 | Novo Nordisk Investigational Site | Phoenix | Arizona | United States | 85006 |
| 5 | Novo Nordisk Investigational Site | Phoenix | Arizona | United States | 85020 |
| 6 | Novo Nordisk Investigational Site | Little Rock | Arkansas | United States | 72205 |
| 7 | Novo Nordisk Investigational Site | Banning | California | United States | 92220 |
| 8 | Novo Nordisk Investigational Site | Chula Vista | California | United States | 91911 |
| 9 | Novo Nordisk Investigational Site | Concord | California | United States | 94520 |
| 10 | Novo Nordisk Investigational Site | Escondido | California | United States | 92025 |
| 11 | Novo Nordisk Investigational Site | Gardena | California | United States | 90247 |
| 12 | Novo Nordisk Investigational Site | La Mesa | California | United States | 91942 |
| 13 | Novo Nordisk Investigational Site | Loma Linda | California | United States | 92354 |
| 14 | Novo Nordisk Investigational Site | Mission Hills | California | United States | 91345 |
| 15 | Novo Nordisk Investigational Site | Palm Springs | California | United States | 92262 |
| 16 | Novo Nordisk Investigational Site | Panorama City | California | United States | 91402 |
| 17 | Novo Nordisk Investigational Site | San Diego | California | United States | 92111 |
| 18 | Novo Nordisk Investigational Site | Santa Ana | California | United States | 92704 |
| 19 | Novo Nordisk Investigational Site | Toluca Lake | California | United States | 91602 |
| 20 | Novo Nordisk Investigational Site | Colorado Springs | Colorado | United States | 80906 |
| 21 | Novo Nordisk Investigational Site | Jacksonville | Florida | United States | 32204 |
| 22 | Novo Nordisk Investigational Site | Miami | Florida | United States | 33144 |
| 23 | Novo Nordisk Investigational Site | Miami | Florida | United States | 33155 |
| 24 | Novo Nordisk Investigational Site | Miami | Florida | United States | 33165 |
| 25 | Novo Nordisk Investigational Site | Ocoee | Florida | United States | 34761 |
| 26 | Novo Nordisk Investigational Site | Orange City | Florida | United States | 32763 |
| 27 | Novo Nordisk Investigational Site | Orlando | Florida | United States | 32804 |
| 28 | Novo Nordisk Investigational Site | Orlando | Florida | United States | 32806 |
| 29 | Novo Nordisk Investigational Site | Oviedo | Florida | United States | 32765 |
| 30 | Novo Nordisk Investigational Site | Pembroke Pines | Florida | United States | 33027 |
| 31 | Novo Nordisk Investigational Site | Conyers | Georgia | United States | 30094 |
| 32 | Novo Nordisk Investigational Site | Macon | Georgia | United States | 31210 |
| 33 | Novo Nordisk Investigational Site | Marietta | Georgia | United States | 30067 |
| 34 | Novo Nordisk Investigational Site | Roswell | Georgia | United States | 30076 |
| 35 | Novo Nordisk Investigational Site | Honolulu | Hawaii | United States | 96813 |
| 36 | Novo Nordisk Investigational Site | Boise | Idaho | United States | 83702 |
| 37 | Novo Nordisk Investigational Site | Meridian | Idaho | United States | 83646 |
| 38 | Novo Nordisk Investigational Site | Chicago | Illinois | United States | 60607 |
| 39 | Novo Nordisk Investigational Site | Gurnee | Illinois | United States | 60031 |
| 40 | Novo Nordisk Investigational Site | Skokie | Illinois | United States | 60077 |
| 41 | Novo Nordisk Investigational Site | West Des Moines | Iowa | United States | 50265 |
| 42 | Novo Nordisk Investigational Site | Newton | Kansas | United States | 67114 |
| 43 | Novo Nordisk Investigational Site | Topeka | Kansas | United States | 66606 |
| 44 | Novo Nordisk Investigational Site | Lafayette | Louisiana | United States | 70508 |
| 45 | Novo Nordisk Investigational Site | New Bedford | Massachusetts | United States | 02740 |
| 46 | Novo Nordisk Investigational Site | Gulfport | Mississippi | United States | 39503 |
| 47 | Novo Nordisk Investigational Site | Chesterfield | Missouri | United States | 63017 |
| 48 | Novo Nordisk Investigational Site | Trenton | New Jersey | United States | 08611 |
| 49 | Novo Nordisk Investigational Site | Albuquerque | New Mexico | United States | 87107 |
| 50 | Novo Nordisk Investigational Site | Albany | New York | United States | 12203 |
| 51 | Novo Nordisk Investigational Site | East Syracuse | New York | United States | 13057 |
| 52 | Novo Nordisk Investigational Site | West Seneca | New York | United States | 14224 |
| 53 | Novo Nordisk Investigational Site | Westfield | New York | United States | 14787 |
| 54 | Novo Nordisk Investigational Site | Chapel Hill | North Carolina | United States | 27514 |
| 55 | Novo Nordisk Investigational Site | Greensboro | North Carolina | United States | 27408 |
| 56 | Novo Nordisk Investigational Site | Morehead City | North Carolina | United States | 28557 |
| 57 | Novo Nordisk Investigational Site | Statesville | North Carolina | United States | 28625 |
| 58 | Novo Nordisk Investigational Site | Wilmington | North Carolina | United States | 28401 |
| 59 | Novo Nordisk Investigational Site | Dublin | Ohio | United States | 43016 |
| 60 | Novo Nordisk Investigational Site | Norman | Oklahoma | United States | 73069 |
| 61 | Novo Nordisk Investigational Site | Cumberland | Rhode Island | United States | 02864 |
| 62 | Novo Nordisk Investigational Site | East Greenwich | Rhode Island | United States | 02818 |
| 63 | Novo Nordisk Investigational Site | Anderson | South Carolina | United States | 29621 |
| 64 | Novo Nordisk Investigational Site | Gaffney | South Carolina | United States | 29340 |
| 65 | Novo Nordisk Investigational Site | Simpsonville | South Carolina | United States | 29681-1538 |
| 66 | Novo Nordisk Investigational Site | Spartanburg | South Carolina | United States | 29303 |
| 67 | Novo Nordisk Investigational Site | Bristol | Tennessee | United States | 37620-7352 |
| 68 | Novo Nordisk Investigational Site | Kingsport | Tennessee | United States | 37660 |
| 69 | Novo Nordisk Investigational Site | Nashville | Tennessee | United States | 37203 |
| 70 | Novo Nordisk Investigational Site | Arlington | Texas | United States | 76012-4637 |
| 71 | Novo Nordisk Investigational Site | Bellaire | Texas | United States | 77401 |
| 72 | Novo Nordisk Investigational Site | Cedar Park | Texas | United States | 78613 |
| 73 | Novo Nordisk Investigational Site | Dallas | Texas | United States | 75230 |
| 74 | Novo Nordisk Investigational Site | Dallas | Texas | United States | 75231 |
| 75 | Novo Nordisk Investigational Site | Dallas | Texas | United States | 75234 |
| 76 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77040 |
| 77 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77061 |
| 78 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77079 |
| 79 | Novo Nordisk Investigational Site | Katy | Texas | United States | 77450 |
| 80 | Novo Nordisk Investigational Site | Kerrville | Texas | United States | 78028 |
| 81 | Novo Nordisk Investigational Site | San Antonio | Texas | United States | 78229 |
| 82 | Novo Nordisk Investigational Site | San Antonio | Texas | United States | 78233 |
| 83 | Novo Nordisk Investigational Site | Shavano Park | Texas | United States | 78231 |
| 84 | Novo Nordisk Investigational Site | Tomball | Texas | United States | 77375 |
| 85 | Novo Nordisk Investigational Site | Sandy | Utah | United States | 84093 |
| 86 | Novo Nordisk Investigational Site | West Jordan | Utah | United States | 84088 |
| 87 | Novo Nordisk Investigational Site | Newport News | Virginia | United States | 23606 |
| 88 | Novo Nordisk Investigational Site | Renton | Washington | United States | 98057 |
| 89 | Novo Nordisk Investigational Site | Green Bay | Wisconsin | United States | 54303 |
| 90 | Novo Nordisk Investigational Site | Caba | Buenos Aires | Argentina | C1128 AAF |
| 91 | Novo Nordisk Investigational Site | Buenos Aires | Argentina | C1023AAB | |
| 92 | Novo Nordisk Investigational Site | Buenos Aires | Argentina | C1425AGC | |
| 93 | Novo Nordisk Investigational Site | Caba | Argentina | C1119ACN | |
| 94 | Novo Nordisk Investigational Site | Caba | Argentina | C1180AAX | |
| 95 | Novo Nordisk Investigational Site | Rosario | Argentina | S2000CUD | |
| 96 | Novo Nordisk Investigational Site | Camperdown | New South Wales | Australia | 2050 |
| 97 | Novo Nordisk Investigational Site | Darlinghurst | New South Wales | Australia | 2010 |
| 98 | Novo Nordisk Investigational Site | Merewether | New South Wales | Australia | 2291 |
| 99 | Novo Nordisk Investigational Site | Meadowbrook | Queensland | Australia | 4131 |
| 100 | Novo Nordisk Investigational Site | Oaklands Park | South Australia | Australia | 5046 |
| 101 | Novo Nordisk Investigational Site | Fitzroy | Victoria | Australia | 3065 |
| 102 | Novo Nordisk Investigational Site | Melbourne | Victoria | Australia | 3004 |
| 103 | Novo Nordisk Investigational Site | Curitiba | Parana | Brazil | 80030-480 |
| 104 | Novo Nordisk Investigational Site | São Paulo | Sao Paulo | Brazil | 01228-000 |
| 105 | Novo Nordisk Investigational Site | São Paulo | Sao Paulo | Brazil | 01228-200 |
| 106 | Novo Nordisk Investigational Site | Burgas | Bulgaria | 8000 | |
| 107 | Novo Nordisk Investigational Site | Gotse Delchev | Bulgaria | 2900 | |
| 108 | Novo Nordisk Investigational Site | Kardzhali | Bulgaria | 6600 | |
| 109 | Novo Nordisk Investigational Site | Lom | Bulgaria | 3600 | |
| 110 | Novo Nordisk Investigational Site | Razgrad | Bulgaria | 7200 | |
| 111 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1202 | |
| 112 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1756 | |
| 113 | Novo Nordisk Investigational Site | Varna | Bulgaria | 9000 | |
| 114 | Novo Nordisk Investigational Site | Varna | Bulgaria | 9010 | |
| 115 | Novo Nordisk Investigational Site | Calgary | Alberta | Canada | T2H 2G4 |
| 116 | Novo Nordisk Investigational Site | Sherwood Park | Alberta | Canada | T8H 0N2 |
| 117 | Novo Nordisk Investigational Site | Surrey | British Columbia | Canada | V3Z 2N6 |
| 118 | Novo Nordisk Investigational Site | Moncton | New Brunswick | Canada | E1G 1A7 |
| 119 | Novo Nordisk Investigational Site | Barrie | Ontario | Canada | L4N 7L3 |
| 120 | Novo Nordisk Investigational Site | Brampton | Ontario | Canada | L6S 0C6 |
| 121 | Novo Nordisk Investigational Site | Concord | Ontario | Canada | L4K 4M2 |
| 122 | Novo Nordisk Investigational Site | Etobicoke | Ontario | Canada | M9R 4E1 |
| 123 | Novo Nordisk Investigational Site | London | Ontario | Canada | N5W 6A2 |
| 124 | Novo Nordisk Investigational Site | Markham | Ontario | Canada | L3P 7P2 |
| 125 | Novo Nordisk Investigational Site | Nepean | Ontario | Canada | K2J 0V2 |
| 126 | Novo Nordisk Investigational Site | Oshawa | Ontario | Canada | L1G4T3 |
| 127 | Novo Nordisk Investigational Site | Oshawa | Ontario | Canada | L1J 2K9 |
| 128 | Novo Nordisk Investigational Site | Toronto | Ontario | Canada | M4G 3E8 |
| 129 | Novo Nordisk Investigational Site | Toronto | Ontario | Canada | M6G 1M2 |
| 130 | Novo Nordisk Investigational Site | Montreal | Quebec | Canada | H4N 2W2 |
| 131 | Novo Nordisk Investigational Site | Pointe-Claire | Quebec | Canada | H9R 4S3 |
| 132 | Novo Nordisk Investigational Site | Saint-Laurent | Quebec | Canada | H4T 1Z9 |
| 133 | Novo Nordisk Investigational Site | Sherbrooke | Quebec | Canada | J1J 2G2 |
| 134 | Novo Nordisk Investigational Site | Terrebonne | Quebec | Canada | J6X 4P7 |
| 135 | Novo Nordisk Investigational Site | Quebec | Canada | G1V 4W2 | |
| 136 | Novo Nordisk Investigational Site | Nanjing | Jiangsu | China | 210011 |
| 137 | Novo Nordisk Investigational Site | Suzhou | Jiangsu | China | 215002 |
| 138 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 80001 | |
| 139 | Novo Nordisk Investigational Site | Bucaramange | Colombia | 681007 | |
| 140 | Novo Nordisk Investigational Site | Cali | Colombia | 760042 | |
| 141 | Novo Nordisk Investigational Site | Monteria | Colombia | 230001 | |
| 142 | Novo Nordisk Investigational Site | Zagreb | Grad Zagreb | Croatia | 10000 |
| 143 | Novo Nordisk Investigational Site | Osijek | Osječko - Baranjska Županija | Croatia | 31000 |
| 144 | Novo Nordisk Investigational Site | Rijeka | Primorsko - Goranska Županija | Croatia | 51 000 |
| 145 | Novo Nordisk Investigational Site | Opatija | Croatia | 51 410 | |
| 146 | Novo Nordisk Investigational Site | Slavonski Brod | Croatia | 35 000 | |
| 147 | Novo Nordisk Investigational Site | Varazdin | Croatia | 42 000 | |
| 148 | Novo Nordisk Investigational Site | Praha 4 | Czech Republic | Czechia | 140 21 |
| 149 | Novo Nordisk Investigational Site | Brno | Czechia | 602 00 | |
| 150 | Novo Nordisk Investigational Site | Broumov | Czechia | 550 01 | |
| 151 | Novo Nordisk Investigational Site | Holešov | Czechia | 76901 | |
| 152 | Novo Nordisk Investigational Site | Plzeň 3 | Czechia | 301 00 | |
| 153 | Novo Nordisk Investigational Site | Praha 1 | Czechia | 110 00 | |
| 154 | Novo Nordisk Investigational Site | Praha 4 | Czechia | 140 00 | |
| 155 | Novo Nordisk Investigational Site | Aarhus N | Denmark | 8200 | |
| 156 | Novo Nordisk Investigational Site | Herlev | Denmark | 2730 | |
| 157 | Novo Nordisk Investigational Site | Hillerød | Denmark | 3400 | |
| 158 | Novo Nordisk Investigational Site | Hvidovre | Denmark | 2650 | |
| 159 | Novo Nordisk Investigational Site | København | Denmark | 2400 | |
| 160 | Novo Nordisk Investigational Site | Odense C | Denmark | 5000 | |
| 161 | Novo Nordisk Investigational Site | Jyväskylä | Finland | 40100 | |
| 162 | Novo Nordisk Investigational Site | Seinäjoki | Finland | 60220 | |
| 163 | Novo Nordisk Investigational Site | Tampere | Finland | 33100 | |
| 164 | Novo Nordisk Investigational Site | Turku | Finland | 20520 | |
| 165 | Novo Nordisk Investigational Site | Berlin | Germany | 13597 | |
| 166 | Novo Nordisk Investigational Site | Daaden | Germany | 57567 | |
| 167 | Novo Nordisk Investigational Site | Dortmund | Germany | 44137 | |
| 168 | Novo Nordisk Investigational Site | Dresden | Germany | 01307 | |
| 169 | Novo Nordisk Investigational Site | Elsterwerda | Germany | 04910 | |
| 170 | Novo Nordisk Investigational Site | Essen | Germany | 45136 | |
| 171 | Novo Nordisk Investigational Site | Gelnhausen | Germany | 63571 | |
| 172 | Novo Nordisk Investigational Site | Hamburg | Germany | 21109 | |
| 173 | Novo Nordisk Investigational Site | Hamburg | Germany | 22041 | |
| 174 | Novo Nordisk Investigational Site | Lingen | Germany | 49808 | |
| 175 | Novo Nordisk Investigational Site | Ludwigshafen | Germany | 67059 | |
| 176 | Novo Nordisk Investigational Site | Lübeck | Germany | 23562 | |
| 177 | Novo Nordisk Investigational Site | München | Germany | 81667 | |
| 178 | Novo Nordisk Investigational Site | Oldenburg in Holstein | Germany | 23758 | |
| 179 | Novo Nordisk Investigational Site | Zwenkau | Germany | 04442 | |
| 180 | Novo Nordisk Investigational Site | Nea Efkarpia | Thessaloniki | Greece | 56429 |
| 181 | Novo Nordisk Investigational Site | Athens | Greece | 115 25 | |
| 182 | Novo Nordisk Investigational Site | Athens | Greece | GR-11527 | |
| 183 | Novo Nordisk Investigational Site | Athens | Greece | GR-15125 | |
| 184 | Novo Nordisk Investigational Site | Haidari-Athens | Greece | GR-12462 | |
| 185 | Novo Nordisk Investigational Site | Larissa | Greece | GR-41110 | |
| 186 | Novo Nordisk Investigational Site | Thessaloniki | Greece | 54636 | |
| 187 | Novo Nordisk Investigational Site | Thessaloniki | Greece | GR-54621 | |
| 188 | Novo Nordisk Investigational Site | Thessaloniki | Greece | GR-54642 | |
| 189 | Novo Nordisk Investigational Site | Thessaloniki | Greece | GR-54643 | |
| 190 | Novo Nordisk Investigational Site | Szeged | Csongrád-Csanád | Hungary | H-6725 |
| 191 | Novo Nordisk Investigational Site | Debrecen | Hajdu-Bihar | Hungary | 4032 |
| 192 | Novo Nordisk Investigational Site | Budapest | Hungary | 1036 | |
| 193 | Novo Nordisk Investigational Site | Budapest | Hungary | 1106 | |
| 194 | Novo Nordisk Investigational Site | Budapest | Hungary | 1134 | |
| 195 | Novo Nordisk Investigational Site | Kaposvár | Hungary | 7400 | |
| 196 | Novo Nordisk Investigational Site | Nagykanizsa | Hungary | 8800 | |
| 197 | Novo Nordisk Investigational Site | Szombathely | Hungary | H-9700 | |
| 198 | Novo Nordisk Investigational Site | Zalaegerszeg | Hungary | 8900 | |
| 199 | Novo Nordisk Investigational Site | Vijaywada | Andhra Pradesh | India | 520002 |
| 200 | Novo Nordisk Investigational Site | Guwahati | Assam | India | 781032 |
| 201 | Novo Nordisk Investigational Site | Bangalore | Karnataka | India | 560092 |
| 202 | Novo Nordisk Investigational Site | Mysuru | Karnataka | India | 570001 |
| 203 | Novo Nordisk Investigational Site | Mumbai | Maharashtra | India | 400008 |
| 204 | Novo Nordisk Investigational Site | Thane | Maharashtra | India | 421004 |
| 205 | Novo Nordisk Investigational Site | Jaipur | Rajasthan | India | 302004 |
| 206 | Novo Nordisk Investigational Site | Chennai | Tamil Nadu | India | 600086 |
| 207 | Novo Nordisk Investigational Site | Coimbatore | Tamil Nadu | India | 641018 |
| 208 | Novo Nordisk Investigational Site | Hyderabad | Telangana | India | 500004 |
| 209 | Novo Nordisk Investigational Site | Hyderabad | Telangana | India | 500072 |
| 210 | Novo Nordisk Investigational Site | Kolkata | West Bengal | India | 700054 |
| 211 | Novo Nordisk Investigational Site | Ahmedabad | India | 390013 | |
| 212 | Novo Nordisk Investigational Site | Chandigarh | India | 160012 | |
| 213 | Novo Nordisk Investigational Site | New Delhi | India | 110001 | |
| 214 | Novo Nordisk Investigational Site | Haifa | Israel | 35152 | |
| 215 | Novo Nordisk Investigational Site | Herzlia | Israel | 4630945 | |
| 216 | Novo Nordisk Investigational Site | Holon | Israel | 58100 | |
| 217 | Novo Nordisk Investigational Site | Jerusalem | Israel | 91120 | |
| 218 | Novo Nordisk Investigational Site | Rehovot | Israel | 76100 | |
| 219 | Novo Nordisk Investigational Site | Tel Hashomer | Israel | 52621 | |
| 220 | Novo Nordisk Investigational Site | Firenze | Fi | Italy | 50134 |
| 221 | Novo Nordisk Investigational Site | Milano | MI | Italy | 20132 |
| 222 | Novo Nordisk Investigational Site | Arezzo | Italy | 52100 | |
| 223 | Novo Nordisk Investigational Site | Bergamo | Italy | 24127 | |
| 224 | Novo Nordisk Investigational Site | Catanzaro | Italy | 88100 | |
| 225 | Novo Nordisk Investigational Site | Chieti Scalo | Italy | 66100 | |
| 226 | Novo Nordisk Investigational Site | Milano | Italy | 20157 | |
| 227 | Novo Nordisk Investigational Site | Napoli | Italy | 80131 | |
| 228 | Novo Nordisk Investigational Site | Palermo | Italy | 90127 | |
| 229 | Novo Nordisk Investigational Site | Roma | Italy | 00161 | |
| 230 | Novo Nordisk Investigational Site | Rome | Italy | 00168 | |
| 231 | Novo Nordisk Investigational Site | Verona | Italy | 37126 | |
| 232 | Novo Nordisk Investigational Site | Ibaraki | Japan | 311-0113 | |
| 233 | Novo Nordisk Investigational Site | Osaka-shi, Osaka | Japan | 530-8480 | |
| 234 | Novo Nordisk Investigational Site | Tokyo | Japan | 103-0027 | |
| 235 | Novo Nordisk Investigational Site | Tokyo | Japan | 104-0031 | |
| 236 | Novo Nordisk Investigational Site | Bucheon-si | Gyeonggi-do | Korea, Republic of | 14647 |
| 237 | Novo Nordisk Investigational Site | Daegu | Korea, Republic of | 42415 | |
| 238 | Novo Nordisk Investigational Site | Gwangju | Korea, Republic of | 501-717 | |
| 239 | Novo Nordisk Investigational Site | Seoul | Korea, Republic of | 02447 | |
| 240 | Novo Nordisk Investigational Site | Seoul | Korea, Republic of | 02841 | |
| 241 | Novo Nordisk Investigational Site | Seoul | Korea, Republic of | 03080 | |
| 242 | Novo Nordisk Investigational Site | Seoul | Korea, Republic of | 03181 | |
| 243 | Novo Nordisk Investigational Site | Mexicali | Baja California | Mexico | 21200 |
| 244 | Novo Nordisk Investigational Site | Guadalajara | Jalisco | Mexico | 44600 |
| 245 | Novo Nordisk Investigational Site | Guadalajara | Jalisco | Mexico | 44670 |
| 246 | Novo Nordisk Investigational Site | Ciudad Madero | Tamaulipas | Mexico | 89440 |
| 247 | Novo Nordisk Investigational Site | Lodz | Lodzkie | Poland | 93-513 |
| 248 | Novo Nordisk Investigational Site | Żyrardów | Masovian | Poland | 96-300 |
| 249 | Novo Nordisk Investigational Site | Warszawa | Mazovian Voivodeship | Poland | 02-117 |
| 250 | Novo Nordisk Investigational Site | Bialystok | Podlaskie | Poland | 15-435 |
| 251 | Novo Nordisk Investigational Site | Bialystok | Poland | 15-351 | |
| 252 | Novo Nordisk Investigational Site | Chrzanow | Poland | 32-500 | |
| 253 | Novo Nordisk Investigational Site | Dąbrowa-Górnicza | Poland | 41-300 | |
| 254 | Novo Nordisk Investigational Site | Gorzow Wielkopolski | Poland | 66-400 | |
| 255 | Novo Nordisk Investigational Site | Lublin | Poland | 20-362 | |
| 256 | Novo Nordisk Investigational Site | Pulawy | Poland | 24-100 | |
| 257 | Novo Nordisk Investigational Site | Rzeszow | Poland | 35-055 | |
| 258 | Novo Nordisk Investigational Site | Tychy | Poland | 43-100 | |
| 259 | Novo Nordisk Investigational Site | Zgierz | Poland | 95-100 | |
| 260 | Novo Nordisk Investigational Site | Staszow | Świętokrzyskie | Poland | 28-200 |
| 261 | Novo Nordisk Investigational Site | Pitesti | Arges | Romania | 110283 |
| 262 | Novo Nordisk Investigational Site | Ploiesti | Prahova | Romania | 100179 |
| 263 | Novo Nordisk Investigational Site | Ploiesti | Prahova | Romania | 100342 |
| 264 | Novo Nordisk Investigational Site | Zalau | Salaj | Romania | 450112 |
| 265 | Novo Nordisk Investigational Site | Bacau | Romania | 600154 | |
| 266 | Novo Nordisk Investigational Site | Brasov | Romania | 500283 | |
| 267 | Novo Nordisk Investigational Site | Bucharest | Romania | 020475 | |
| 268 | Novo Nordisk Investigational Site | Bucuresti | Romania | 050913 | |
| 269 | Novo Nordisk Investigational Site | Cluj Napoca | Romania | 400006 | |
| 270 | Novo Nordisk Investigational Site | Galati | Romania | 800001 | |
| 271 | Novo Nordisk Investigational Site | Mangalia | Romania | 905500 | |
| 272 | Novo Nordisk Investigational Site | Pascani | Romania | 705200 | |
| 273 | Novo Nordisk Investigational Site | Novi Sad | Vojvodina | Serbia | 21000 |
| 274 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11000 | |
| 275 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11080 | |
| 276 | Novo Nordisk Investigational Site | Kragujevac | Serbia | 34000 | |
| 277 | Novo Nordisk Investigational Site | Bardejov | Slovakia | 08501 | |
| 278 | Novo Nordisk Investigational Site | Kosice | Slovakia | 040 01 | |
| 279 | Novo Nordisk Investigational Site | Malacky | Slovakia | 90101 | |
| 280 | Novo Nordisk Investigational Site | Presov | Slovakia | 080 01 | |
| 281 | Novo Nordisk Investigational Site | Prievidza | Slovakia | 971 01 | |
| 282 | Novo Nordisk Investigational Site | Ruzomberok | Slovakia | 034 01 | |
| 283 | Novo Nordisk Investigational Site | Sabinov | Slovakia | 083 01 | |
| 284 | Novo Nordisk Investigational Site | Surany | Slovakia | 942 01 | |
| 285 | Novo Nordisk Investigational Site | Trebisov | Slovakia | 075 01 | |
| 286 | Novo Nordisk Investigational Site | Ziar nad Hronom | Slovakia | 965 01 | |
| 287 | Novo Nordisk Investigational Site | Kocevje | Slovenia | 1330 | |
| 288 | Novo Nordisk Investigational Site | Koper | Slovenia | 6000 | |
| 289 | Novo Nordisk Investigational Site | Ljubljana | Slovenia | 1000 | |
| 290 | Novo Nordisk Investigational Site | Maribor | Slovenia | 2000 | |
| 291 | Novo Nordisk Investigational Site | Nova Gorica | Slovenia | 5000 | |
| 292 | Novo Nordisk Investigational Site | Sempeter pri Gorici | Slovenia | 5290 | |
| 293 | Novo Nordisk Investigational Site | Topolšica | Slovenia | 3326 | |
| 294 | Novo Nordisk Investigational Site | Port Elizabeth | Eastern Cape | South Africa | 6001 |
| 295 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 2001 |
| 296 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 2196 |
| 297 | Novo Nordisk Investigational Site | Kempton Park | Gauteng | South Africa | 1619 |
| 298 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0186 |
| 299 | Novo Nordisk Investigational Site | Paarl | Western Cape | South Africa | 7646 |
| 300 | Novo Nordisk Investigational Site | Barcelona | Spain | 08035 | |
| 301 | Novo Nordisk Investigational Site | La Coruña | Spain | 15006 | |
| 302 | Novo Nordisk Investigational Site | La Roca del Vallés | Spain | 08430 | |
| 303 | Novo Nordisk Investigational Site | Móstoles | Spain | 28935 | |
| 304 | Novo Nordisk Investigational Site | Palma de Mallorca | Spain | 07198 | |
| 305 | Novo Nordisk Investigational Site | Segovia | Spain | 40002 | |
| 306 | Novo Nordisk Investigational Site | Sevilla | Spain | 41010 | |
| 307 | Novo Nordisk Investigational Site | Valencia | Spain | 46026 | |
| 308 | Novo Nordisk Investigational Site | Lund | Sweden | 221 85 | |
| 309 | Novo Nordisk Investigational Site | Lund | Sweden | 222 21 | |
| 310 | Novo Nordisk Investigational Site | Malmö | Sweden | 205 02 | |
| 311 | Novo Nordisk Investigational Site | Stockholm | Sweden | 171 76 | |
| 312 | Novo Nordisk Investigational Site | Örebro | Sweden | 701 85 | |
| 313 | Novo Nordisk Investigational Site | Adana | Turkey | 01130 | |
| 314 | Novo Nordisk Investigational Site | Antalya | Turkey | 07058 | |
| 315 | Novo Nordisk Investigational Site | Eskisehir | Turkey | 26040 | |
| 316 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34098 | |
| 317 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34371 | |
| 318 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34390 | |
| 319 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34480 | |
| 320 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34722 | |
| 321 | Novo Nordisk Investigational Site | Tekirdag | Turkey | 59030 | |
| 322 | Novo Nordisk Investigational Site | Stevenage | Hertfordshire | United Kingdom | SG1 4AB |
| 323 | Novo Nordisk Investigational Site | Bath | United Kingdom | BA2 3HT | |
| 324 | Novo Nordisk Investigational Site | Blackburn | United Kingdom | BB2 1AX | |
| 325 | Novo Nordisk Investigational Site | Dundee | United Kingdom | DD1 9SY | |
| 326 | Novo Nordisk Investigational Site | Foresterhill | United Kingdom | AB25 2ZP | |
| 327 | Novo Nordisk Investigational Site | Liverpool | United Kingdom | L9 7AL | |
| 328 | Novo Nordisk Investigational Site | Norwich | United Kingdom | NR4 7UY | |
| 329 | Novo Nordisk Investigational Site | Pickering | United Kingdom | YO18 8BL | |
| 330 | Novo Nordisk Investigational Site | Southampton | United Kingdom | SO30 3JB | |
| 331 | Novo Nordisk Investigational Site | Swansea | United Kingdom | SA2 8PP | |
| 332 | Novo Nordisk Investigational Site | Truro | United Kingdom | TR1 3LJ |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT06065540
Other Study ID Numbers:
- NN9388-4896
- U1111-1283-0427
- 2022-502678-18
First Posted:
Oct 4, 2023
Last Update Posted:
Oct 4, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: